Gallic acid emerges as a multitarget agent capable of alleviating depression-pain comorbidity through selective inhibition of P2X7 receptor expression across hippocampal, spinal cord, and dorsal root ganglion tissues (Wen et al., 2022). This evidence concerns the gene P2RX7 and depressive disorder.